Healionics
Founded Year
2007Stage
Series A - III | AliveTotal Raised
$34.61MLast Raised
$2.68M | 1 mo agoAbout Healionics
Healionics operates as a clinical-stage company. It develops and manufactures biomaterials for implanted medical devices to induce an integrated healing response, overcoming fibrotic reactions and infection issues to enhance medical device performance. It was founded in 2007 and is based in Seattle, Washington.
Loading...
Loading...
Healionics Patents
Healionics has filed 9 patents.
The 3 most popular patent topics include:
- implants (medicine)
- vascular surgery
- angiology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/24/2016 | 11/24/2020 | Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology, Blindness, Rare diseases | Grant |
Application Date | 6/24/2016 |
|---|---|
Grant Date | 11/24/2020 |
Title | |
Related Topics | Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology, Blindness, Rare diseases |
Status | Grant |
Latest Healionics News
May 17, 2021
Healionics raises $4.7M to commercialize artificial blood vessel tech May 13, 2021 at 10:58 am Share 7 Healionics’ STARgraft vascular graft acts as an artificial blood vessel for dialysis patients. (Healionics Photo) New funding: Seattle-based medical technology company Healionics raised a $4.7 million round led by Keiretsu Capital to help commercialize its artificial blood vessel called STARgraft for patients who undergo dialysis treatment. Patients with failed kidneys can undergo dialysis several times per week to filter waste from the bloodstream. In administering the treatment, physicians often use a vascular graft to maintain access to the bloodstream, but current grafts often fail due to blockages, also known as vascular occlusion. STARgraft aims to provide high resistance to occlusion. “We are targeting early next year for commercial launch of STARgraft,” Healionics CEO Mike Connolly said in a statement. “This novel synthetic blood vessel, based on our proprietary STAR biomaterial technology, has the potential to improve the lives of dialysis patients by reducing the frequency and severity of infections and the frequency of interventions required to maintain dialysis access.” The cash will be used to complete a second human study and obtain FDA clearance. Healionics also said it converted $5.2 million in outstanding notes and interest to equity. Message from the Underwriter
Healionics Frequently Asked Questions (FAQ)
When was Healionics founded?
Healionics was founded in 2007.
Where is Healionics's headquarters?
Healionics's headquarters is located at 2121 North 35th Street, Seattle.
What is Healionics's latest funding round?
Healionics's latest funding round is Series A - III.
How much did Healionics raise?
Healionics raised a total of $34.61M.
Who are the investors of Healionics?
Investors of Healionics include MedTech Innovator, Keiretsu Capital, Social Venture Partners, Paycheck Protection Program, NuFund Venture Group and 12 more.
Who are Healionics's competitors?
Competitors of Healionics include Tepha, MedShape, Viveve Medical, EndoMedix, Elastagen and 7 more.
Loading...
Compare Healionics to Competitors
Serica is a medical device company focused on the development of silk-based biomaterial platforms that may be used in tissue repair. The company's approach leverages natural silk in combination with advances in biomedical engineering to address needs in the repair of damaged connective tissue, caused by disease, trauma, or aging. Serica's products are being studied for use in orthopaedics and sports medicine, aesthetic and reconstructive plastic surgery, and multiple additional structural tissue repair applications.
Suneva Medical is a privately-held company that focuses on the development, manufacturing, and commercialization of regenerative aesthetic products. The company's main offerings include dermal fillers, PRP technology, and fat graft products, all designed to enhance aesthetic outcomes and patient satisfaction. Suneva Medical primarily serves the aesthetic markets. Suneva Medical was formerly known as Artes Medical. It was founded in 2009 and is based in San Diego, California.
IN2BATE is prepared to enter the emergency medicine market by offering a cricothyroidotomy device. A cricothyroidotomy is an emergency procedure that is performed on patients suffering from an obstructed airway, usually caused by a trauma accident. Thorough market research has allowed for us to create a strategic advantage over the competition by creating a solution for an uncontested market space. The company's target market includes hospitals--specifically emergency departments, ambulance service companies, ambulance supply companies, and emergency response units.
The resources necessary to transform a medical device concept into a commercially viable reality are enormous. Appropriate funding in addition to Food and Drug Administration ( FDA) experience, engineering and rapid prototyping are essential in order to have any reasonable chance for success. To this end, SpringMed Group is a medical device business accelerator that has been designed and organized around core competencies that will substantially improve the development time line and successful launch of new and medical devices.
Es Vascular is a company focused on the medical industry, specifically in the distribution of medical supplies. The company offers a range of products including medical devices for urology, surgery, anesthesiology, tissue regeneration, wound management, biopsy needles, and gynecology. These products are designed to treat various medical conditions and assist in different medical procedures. It was founded in 2000 and is based in Israel.
Biomimedica is developing earlier intervention solutions to treat osteoarthritis that will allow patients to maintain a pain-free, active lifestyle.
Loading...